Five reasons for which it is worth to use zofenopril Review article
Article Sidebar
Published:
Jun 30, 2016
Keywords:
zofenopril, cardiovascular system
Main Article Content
Abstract
Zofenopril belongs to new ACE-inhibitors and contains sulfhydryl group. Drug is distinguished by many unique properties including: lipophilicity, high tissue penetration, long duration of action and hypolipidemic effectiveness. According to controlled, randomized studies it was shown that zofenopril exerted beneficial effects in patients with acute myocardial infarction both with and without accompanying heart failure. During therapy zofenopril is well tolerated.
Article Details
How to Cite
Lewandowski , J., & Abramczyk , P. (2016). Five reasons for which it is worth to use zofenopril. Medycyna Faktow (J EBM), 7(2(23), 19-22. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2361
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Ranadive S.A., Chen A.X., Serajuddin A.T.M.: Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm. Res. 1992; 9: 1480-1486.
2. Cushman D.W., Wang F.L., Fung W.C. et al.: Comparisons “in vitro”, “ex vivo”, and “in vivo” of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 1989; 28: 115S-131S.
3. Cushman D.W., Wang F.L., Fung W.C. et al.: Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am. J. Hypert. 1989; 2: 294-306.
4. Grover G.J., Sleph P.G., Dzwonczyk S. et al.: Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: Relationship between cardiac ACE inhibitor and cardioprotection. J. Pharmacol. Exp. Ther. 1991; 257: 919-929.
5. Subissi A., Evangelista S., Giachetti A.: Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties. Cardiovasc. Drug. Rev. 1999; 17(2): 115-133.
6. DeForrest J.M., Waldron T.L., Krapcho J. et al.: Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. J. Cardiovasc. Pharmacol. 1989; 13: 887-894.
7. Mitchell G.F., Pfeffer M.A., Finn P.V. et al.: Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats. Circulation 1996; 94: 2923-2929.
8. Farsang C.: Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press. Suppl. 2007; 2: 19-24.
9. Narkiewicz K.: Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press. Suppl. 2007; 2: 7-12.
10. van Gilst W.H., de Graeff P.A., de Leeue M.J. et al.: Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilatators. J. Cardiovasc. Pharmacol. 1991; 18: 429-436.
11. Rizos E.C.: Improvement of the lipid profile with zofenopril in hypertensive patients with the metabolit syndrome. The Open Clin. Chemistry J. 2008; 1: 64-68.
12. Ambrosioni E., Borghi C., Magnani B.: The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction. N. Engl. J. Med. 1995; 332: 80-85.
13. Ambrosioni E.: Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am. Heart J. 2007; 153(3): 445.e7-14.
14. van Gilst W.H., Scholtens E., de Graeff P.A. et al.: Differential influences of angiotensin converting-enzyme inhibitors on the coronary circulation. Circulation 1988; 77(Suppl. 1): 24-29.
15. Liu X., Engelman R.M., Ronson J.A. et al.: Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc. Drugs Ther. 1992; 6: 437-443.
16. Cominacini L., Pasini A., Garbin U. et al.: Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am. J. Hypertens. 2002; 15: 891-895.
17. Napoli C., Sica V., de Nigris F. et al.: Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am. Heart J. 2004; 148(1): e5.
18. Mallion J.M.: An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press. Suppl. 2007; 2: 13-18.
19. Farsang C.: Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press. Suppl. 2007; 2: 19-24.
20. Nilsson P.: Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press. Suppl. 2007; 2: 25-30.
21. Borghi C., Ambrosioni E.: Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am. Heart J. 2003; 145(1): 80-87.
22. Borghi C., Ambrosioni E., Novo S. et al.; SMILE-4 Working Party: Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin. Cardiol. 2012; 35(7): 416-23.
2. Cushman D.W., Wang F.L., Fung W.C. et al.: Comparisons “in vitro”, “ex vivo”, and “in vivo” of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 1989; 28: 115S-131S.
3. Cushman D.W., Wang F.L., Fung W.C. et al.: Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am. J. Hypert. 1989; 2: 294-306.
4. Grover G.J., Sleph P.G., Dzwonczyk S. et al.: Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: Relationship between cardiac ACE inhibitor and cardioprotection. J. Pharmacol. Exp. Ther. 1991; 257: 919-929.
5. Subissi A., Evangelista S., Giachetti A.: Preclinical Profile of Zofenopril: An Angiotensin Converting Enzyme Inhibitor with Peculiar Cardioprotective Properties. Cardiovasc. Drug. Rev. 1999; 17(2): 115-133.
6. DeForrest J.M., Waldron T.L., Krapcho J. et al.: Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. J. Cardiovasc. Pharmacol. 1989; 13: 887-894.
7. Mitchell G.F., Pfeffer M.A., Finn P.V. et al.: Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats. Circulation 1996; 94: 2923-2929.
8. Farsang C.: Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press. Suppl. 2007; 2: 19-24.
9. Narkiewicz K.: Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press. Suppl. 2007; 2: 7-12.
10. van Gilst W.H., de Graeff P.A., de Leeue M.J. et al.: Converting enzyme inhibitors and the role of the sulfhydryl group in the potentiation of exo- and endogenous nitrovasodilatators. J. Cardiovasc. Pharmacol. 1991; 18: 429-436.
11. Rizos E.C.: Improvement of the lipid profile with zofenopril in hypertensive patients with the metabolit syndrome. The Open Clin. Chemistry J. 2008; 1: 64-68.
12. Ambrosioni E., Borghi C., Magnani B.: The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction. N. Engl. J. Med. 1995; 332: 80-85.
13. Ambrosioni E.: Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am. Heart J. 2007; 153(3): 445.e7-14.
14. van Gilst W.H., Scholtens E., de Graeff P.A. et al.: Differential influences of angiotensin converting-enzyme inhibitors on the coronary circulation. Circulation 1988; 77(Suppl. 1): 24-29.
15. Liu X., Engelman R.M., Ronson J.A. et al.: Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc. Drugs Ther. 1992; 6: 437-443.
16. Cominacini L., Pasini A., Garbin U. et al.: Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am. J. Hypertens. 2002; 15: 891-895.
17. Napoli C., Sica V., de Nigris F. et al.: Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am. Heart J. 2004; 148(1): e5.
18. Mallion J.M.: An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press. Suppl. 2007; 2: 13-18.
19. Farsang C.: Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press. Suppl. 2007; 2: 19-24.
20. Nilsson P.: Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press. Suppl. 2007; 2: 25-30.
21. Borghi C., Ambrosioni E.: Survival of Myocardial Infarction Long-term Evaluation-2 Working Party. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am. Heart J. 2003; 145(1): 80-87.
22. Borghi C., Ambrosioni E., Novo S. et al.; SMILE-4 Working Party: Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4). Clin. Cardiol. 2012; 35(7): 416-23.